Volume 79, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


We compared plasma maximum concentration (Cmax) and area under the concentration-time curve (AUC) of the antimalarial drug piperaquine in 26 healthy Vietnamese subjects after treatment with either a single oral dose of 500 mg (n = 6) or 1,000 mg (n = 6) of piperaquine phosphate and a three-day course of 500 mg of piperaquine/ day in the fasting state (n = 7) or with food (approximately 17 g fat) (n = 7). The geometric mean plasma Cmax and AUC was 2.8-fold (200 ng/mL versus 70 ng/mL) and 1.9-fold (5,736 ng · h/mL versus 2,999 ng · h/mL), respectively, and higher in subjects receiving the 1,000-mg dose than in those receiving the 500-mg dose. The geometric mean Cmax and AUC was 1.7-fold (198 ng/mL versus 119 ng/mL) and 1.4-fold (11,187 ng · h/mL versus 7,954 ng · h/mL) higher in the fed state than in the fasting state. Piperaquine AUC was proportional to the two doses tested and a moderate-fat meal enhanced the bioavailability of piperaquine by 41%, which should improve the therapeutic efficacy of this drug.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF, 2005. Piperaquine: a resurgent antimalarial drug. Drugs 65 : 75–87. [Google Scholar]
  2. Denis BM, Davis TM, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y, Lim C, Socheat D, 2002. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis 35 : 1469–1476. [Google Scholar]
  3. Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, D’Alessandro U, 2006. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 100 : 1105–1111. [Google Scholar]
  4. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, Lindegardh N, Singtoroj T, Ashley E, Lwin S, Stepniewska K, White NJ, 2006. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367 : 2075–2085. [Google Scholar]
  5. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, 2007. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369 : 757–765. [Google Scholar]
  6. Sim IK, Davis TME, Ilett KF, 2005. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother 49 : 2407–2411. [Google Scholar]
  7. Liu C, Zhang R, Hong X, Huang T, Mi S, Wang N, 2007. Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers. Yakugaku Zasshi 127 : 1709–1714. [Google Scholar]
  8. Ahmed T, Sharma P, Gautam A, Varshney B, Kothari M, Ganguly S, Moehrle JJ, Paliwal J, Saha N, Batra V, 2008. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J Clin Pharmacol 48 : 166–175. [Google Scholar]
  9. Hung T, Davis T, Ilett K, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D, 2003. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 57 : 253–262. [Google Scholar]
  10. Roshammar D, Hai TN, Hietala SF, Huong NV, Ashton M, 2006. Pharmacokinetics of piperaquine after repeated oral administration of the antimlarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol 62 : 335–341. [Google Scholar]
  11. Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, Page-Sharp M, Lin E, Lammey J, Batty KT, Davis TM, 2008. Pharmacokinetics and efficacy of piperaquine and chloroquine in melanesian children with uncomplicated malaria. Antimicrob Agents Chemother 52 : 237–243. [Google Scholar]
  12. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NPJ, McGready R, Ashton M, Nosten F, White NJ, 2008. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 52 : 1052–1061. [Google Scholar]
  13. Lindegardh N, White NJ, Day NPJ, 2005. High throughput assay for the determination of piperaquine in plasma. J Pharm Biomed Anal 39 : 601–605. [Google Scholar]
  14. Gibaldi M, Perrier D, 1982. Pharmacokinetics. Second edition. New York: Dekker.
  15. Tarning J, Lindegardh N, Annerberg A, Singtoroj T, Day NPJ, Ashton M, White NJ, 2005. Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother 49 : 5127–5128. [Google Scholar]
  16. White NJ, 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41 : 1413–1422. [Google Scholar]
  17. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, Kenangalem E, Lindegardh N, Penttinen P, Laihad F, Ebs-worth EP, Anstey NM, Tjitra E, 2007. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother 51 : 4090–4097. [Google Scholar]

Data & Media loading...

  • Received : 07 Mar 2008
  • Accepted : 08 Jul 2008

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error